Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-575 plus carboplatin + paclitaxel versus carboplatin + paclitaxel in untreated advanced NSCLC
2010-023854-35Phase 2Terminated
- Sponsor
- MedImmune
- Start
- Mar 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of Tovetumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by MedImmune. Primary endpoint: Progression-free survival. Started Mar 2011; status: terminated.
02
Drugs
Tovetumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-023854-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023854-35.